Company news

Dimerix Limited news in 2025

Dimerix Limited's news releases, calls and decks from 2025, newest first.

View company

BioMarin to acquire Dimerix US Partner, Amicus Therapeutics

December 21, 2025

DMX-200 ACTION3 Phase 3 trial completes recruitment

December 15, 2025

DMX-200 ACTION3 Phase 3 Trial Completes Recruitment

December 14, 2025

Successful Completion of Planned IDMC Review

November 18, 2025

Successful PARASOL Collaboration Data Analysis Outcome

October 7, 2025

DMX-200 receives Orphan Drug Designation in Japan

September 29, 2025

Appendix 4E and 2025 Annual Report

August 27, 2025

Dimerix receives 1st Development Milestone payment from FUSO

June 29, 2025

ACTION3 Clinical Trial Milestone Recruitment Update

June 12, 2025

1st ACTION3 site in Japan activated and milestone triggered

May 29, 2025

Successful planned IDMC review of ACTION3 trial

May 21, 2025

Dimerix receives initial upfront payment from Amicus

May 5, 2025

Investor Webinar and Presentation

April 30, 2025

Dimerix Licenses DMX-200 in the US

April 30, 2025

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

April 30, 2025

Trading Halt

April 28, 2025

FDA confirms Proteinuria as Primary Endpoint for US approval

April 27, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Dimerix receives initial upfront payment from FUSO

March 3, 2025

Half-Year Financial Report & Appendix 4D - 31 December 2024

February 24, 2025

First Paediatric Patient Recruited for ACTION3

January 15, 2025

Dimerix enters Development and License Agreement for Japan

January 6, 2025

Decks in 2025